(excerpted from
ADHD RESEARCH UPDATE - Vol. 21, July,
1999)
There was a very
important paper that appeared in the May, 1999 issue of
the Journal of the American Academy of Child and
Adolescent Psychiatry on the use of medication for
treating psychiatric disorders in children and
adolescents (Jensen, P.J., Bhatara, V.S., Vitiello, B.,
Hoagwood, K., Feil, M., & Burke, L.B. (1999).
Psychoactive medication prescribing practices for U.S.
children: Gaps between research and clinical
practice). In this paper, the authors examine the
frequency with which different medications are prescribed
in relation to what research data exists for the safety
and efficacy of the different meds. Although
this encompasses disorders other than ADHD, I think this
is quite an interesting and important paper to include in
ADHD RESEARCH UPDATE. This is because I know that
many of you have children who receive medications other
than stimulants, and knowing something about the research
support for these medications would be important.
In addition, many professionals who receive the
newsletter may be involved in prescribing these
medications to the children they treat. There are 8 classes of
medications that were looked at in this paper. Each
class of medication, examples of brand name meds from
each class, and the type of disorder it is typically
prescribed for are presented in the table below. (Note:
The medications listed in the Selected Examples column
are just examples of medications from the general
category.) In terms of the
frequency with which these different classes of
medication are prescribed, the numbers differed somewhat
depending on which national data base the estimates are
based on. Not surprisingly, stimulant medications
are far and away the most frequently prescribed
medication in child psychiatry. The best estimates
available are that stimulant medications were prescribed
in nearly 2 million visits for patients under the age of
18 during 1995. This is between 5 and 10 times the
next most-frequently prescribed class of medications, the
SSRIs. Even the least-frequently prescribed
medication in this listing was estimated to have been
dispensed to thousands of children, however. One clear conclusion
made by the authors is that it is really quite difficult
to obtain accurate estimates of just how often
psychoactive medications are being prescribed to children
and teens in this country. In fact, the best data
that exists is probably on the prescription of stimulant
medications for ADHD. Clearly, having more
accurate data on the use of such medication for children
and teens would be very useful to have. What about the
evidence supporting the efficacy and safety for the use
of such medications in youth? The authors examine
this in relation to what is known about both short- and
long- term efficacy, and short- and long-term
safety. The grading scale they used, and the
criteria for the different grades are shown
below: Efficacy
Ratings A - Efficacy supported
in at least 2 or more randomized, controlled
trials. These would be
studies in which
children's response to medication was compared to how
they responded to a
placebo; B - Efficacy supported
in at least 1 randomized controlled trial; C - Efficacy supported
by "informed" clinical opinion, case reports, or
non-placebo controlled trials. This would generally
be considered only an initial stage in documenting the
efficacy of a pharmacologic treatment; Safety
Ratings A - Low incidence of
adverse event reports to the FDA. That is, adverse
effects that could be attributed to the medication have
been infrequently reported.
Note: This is not the same as having safety data
established based on long-term randomized and controlled
clinical trials. As the authors note, however,
conducting such trials for long-term safety data may be
neither ethical nor feasible. B - Clinically
significant adverse event reports restricted to case
reports and/or anecdotal reports, suggesting possible
rare side effects. C - No data or minimal
data supporting long-term adversity or safety. In other
words, little about the long-term impacts are really
know, one way or the other. Using these criterion,
the grades assigned by the authors based on their review
of the literature are shown below. The conditions
under the general class of medicaqtion indicate the
disorder for which the ratings in that row apply.
For example, stimulant medications for treating ADHD
receive grades of A and B for short- and long-term
efficacy respectively, and grades of A for short- and
long-term safety. As you can see, when the same
type of medication is used to treat different conditions,
and the grades are not always the same. (Sorry, but I was
not able to get things to line up exactly.)
Please note that these
grades are based on the authors' review, and other
experts in the field might conceivably come to somewhat
different conclusions. Overall, however, the
ratings indicate important gaps in current
knowledge. As you can see, not a single of the most
frequently used medications for treating child and
adolescent disorders received grades of A across the
board. Stimulant medications for treating ADHD came
closest, and I think that soon-to-be-published studies on
long-term efficacy will turn this into an A grade quite
shortly. In contrast, the long-term efficacy grade
for every other medication was a C. Remember, this
does not mean that these compounds are not effective for
the designated use. Instead, it means that solid
scientific data that documents long-term efficacy is not
yet available. Of course, this is not that
different from the situation that exists with many
medications that are used to treat a variety of physical
ailments. Even when it comes to short-term
efficacy, however, only two other classes of medication
received A grades for treating a particular
disorder. There are several
important points that can be taken from this excellent
review paper. First, one could certainly make a
case that these medications are being over prescribed,
given the efficacy and safety data that is available to
support their use. For example, given the frequency
with which antidepressant medications are prescribed for
children and teens, the relative lack of scientific
support for this is quite surprising. To date,
there has been but a single study in which an
antidepressant produced significantly better effects than
a placebo in younger depressed patients (this was for
fluoxetine - the generic form of Prozac - and where the
results were 56% improved on fluoxetine vs. 33% on
placebo). Clearly, there is a pressing need for
more scientific study of these medications for treating
children and teens. Second, when one looks
at the data above, it is surprising how much controversy
there continues to be about the use of stimulant
medications for treating ADHD relative to the use of the
other medications listed. Clearly, stimulant
medications have the best established efficacy and safety
data available, even though more work in this area is
also called for. If as much supportive data was
available for these other medications as is currently
available for stimulants, however, we would be much
further along in our knowledge than we currently
are. Finally, I think these
data suggest that one should be cautious about using
medications to treat most psychiatric conditions in
children and teens. With certain exceptions, the
data to support the use of medications is not so
compelling that one would not want to carefully explore
other treatment options. The authors - 3 of
whom are child psychiatrists heavily involved in research
- close their paper with the following
statement: "The lack of safety
and efficacy data for psychotropic medications is of
general concern, not just for parents of children with
mental illness and their physicians, but for all with a
stake in the future of the nation's children." They lay out a set of
recommendations for helping to close these important gaps
in knowledge that will hopefully be heeded by researchers
and pharmaceutical companies in the years ahead.
(table added
by Balance Check)
sertaline
Obsessive compulsive disorde (OCD)
Anxiety disorders
ADHD
ADHD
Tourettes Disorder
agression
(Table
inserted by Balance Check)
----------
Note from Balance Check. This copyrighted information was passed on to you with permission from Dr. Rabiner's research update newsletter (July 1999). The newsletter is excellent and you may wish to subscribe. You can get a sample issue sent to you by e-mail. To do so, click here or send an e-mail to subscribe@helpforadd.com. If you do subscribe, please let Dr. Rabiner know that you were referred by me (Charles Kenyon - balance_check@bigfoot.com). Doing this extends my own subscription and will allow me to continue to post articles from the newsletters on my website. Please note that there are more articles in each newsletter than I post. Other articles in this particular issue included: Differentiating Between ADHD and Pervasive Developmental Disorder, ADHD in Other Cultures: The Prevalence of ADHD Among Brazilian Adolescents, and Diet and ADHD Revisited.
Balance
Check's Five Essential ADD/ADHD Books
List
Balance
Check's Library of ADD / ADHD Books
Balance Check's Links
Pages
Balance Check's ADD
Home Page
© 1999 David Rabiner as to content of excerpted material. © 1998, 1999 Charles K. Kenyon as to HTML coding only
Attention Deficit Hyperativity Disorder is sometimes known as Attention Deficit Disorder, ADD, ADHD, and AD/HD. In the past it was called minimal brain dysfunction, among other things. This paragraph is added to this page to make it more likely that a search engine will pick up this page if you are looking for information using one of those terms.